AUG 25, 2019 8:24 PM PDT

Unprecedented Therapeutic Found Effective for Blood Cancer

WRITTEN BY: Nouran Amin

According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of bone marrow cancer. The cancer is known to be resistant to several standard therapeutics. Findings were published in the The New England Journal of Medicine and involves testing the drug selinexor with dexamethasone--a combination that treated the cancer in a quarter of patients where two of these patients went into complete remission.

In cancer cell biology, proteins and messenger RNAs play a critical role in cancer growth. Selinexor was found to inhibit the export of protein and messenger RNAs from the nucleus of the cancer cell to the cytoplasm resulting in cancer cell death.

"This study proved that a novel, first-in-class drug with a new mechanism of action can kill a patient's cancer cells," said the study's senior author, Sundar Jagannath, MBBS, Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at Mount Sinai. "This proved that the drug worked in patients who had exhausted every other treatment and who would have been placed on hospice care otherwise."

Patients enrolled in the clinical trial, known as the STORM Part 2 Study, who took selinexor and dexamethasone, saw a response within one or two months. Even though no toxicity was present, patients did experience low blood count, nausea, vomiting, and lack of appetite or fatigue.

"This study is meaningful for patients with multiple myeloma who haven't had success on multiple other therapies," said the study's first author Ajai Chari, MD, Director of Clinical Research in the Multiple Myeloma Program at The Tisch Cancer Institute at Mount Sinai. "An increasing number of patients have resistance to the standard drugs used in the treatment of multiple myeloma, and the overall survival in these patients is short, sometimes less than three months."

Selinexor has been approved by the FDA for patients resistant to multiple therapies and the drug is being studied for multiple myeloma as well as in other malignancies such lymphoma and ovarian cancer.

In the Tisch Cancer Institute at Mount Sinai, the study brings a major milestone in myeloma research.

"The Center of Excellence for Multiple Myeloma is part of The Tisch Cancer Institute and uses the most advanced diagnostic and treatment approaches within state-of-the-art facilities of a National Cancer Institute-designated cancer center," said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai. "Coordinated care teams include experts from the Bone Marrow Transplant Program, pathology, radiology, immunology, genomics, infectious diseases, orthopedic surgery, cardiology, and nephrology, and patients will have broad access to comprehensive supportive services, including from social workers, financial counselors, and clergy."

Source: The Mount Sinai School of Medicine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 07, 2020
Cannabis Sciences
Should You Smoke Cannabis Seeds and Stems?
JUN 07, 2020
Should You Smoke Cannabis Seeds and Stems?
When smoking cannabis, people typically use either the flower, buds, or leaves. But what about the seeds and stems? Can ...
JUN 08, 2020
Cancer
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
JUN 08, 2020
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD- ...
JUN 13, 2020
Cannabis Sciences
CBD Kills Brain Cancer Cells in Petri Dish
JUN 13, 2020
CBD Kills Brain Cancer Cells in Petri Dish
Cannabis products are not only popular for their psychoactive effects. An increasing number of companies and researchers ...
JUN 18, 2020
Drug Discovery & Development
A Fat Burning Molecule That Works?
JUN 18, 2020
A Fat Burning Molecule That Works?
Obesity is a US epidemic affecting more than 40 percent of the adults and with a wide array of complications one being e ...
JUN 24, 2020
Drug Discovery & Development
Gilead to Test Inhalable Remdesivir Against COVID-19
JUN 24, 2020
Gilead to Test Inhalable Remdesivir Against COVID-19
Gilead has announced that it will soon start trials for an inhalable form of Remdesivir, the first drug to receive Emerg ...
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
Loading Comments...